Ultragenyx upgraded to Overweight from Equal Weight at Barclays. Barclays analyst Gena Wang upgraded Ultragenyx Pharmaceutical to Overweight and raised her price target for the shares to $74 from $62. The analyst thinks a higher price target for Crysvita could drive upside to revenue growth expectations. She also sees a “reasonable probability of success” for triheptanoin in long-chain fatty acid oxidation disorde and glucose transporter type-1 deficiency syndrome.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.